Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Recurrence 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Advanced Gastric Cancer 2Thoracic Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Osteosarcoma 1Neoplasms by Site 1Mouth Neoplasms 1Lung Neoplasms 1Lung Diseases 1Liver Diseases 1Hodgkin Disease 1Hematologic Neoplasms 1Gestational Trophoblastic Disease 1Gastrointestinal Neoplasms 1

Interventions

Oxaliplatin 14Fluorouracil 11Capecitabine 9Surveys and Questionnaires 8Leucovorin 8Irinotecan 8Cisplatin 8Bevacizumab 8Standard of Care 5Gemcitabine 5Drug Therapy 4S 1 (combination) 3Radiotherapy 3Nivolumab 3Interviews as Topic 3IFL protocol 3Educational Status 3Cyclophosphamide 3Colonoscopy 3Blood Specimen Collection 35,10-methylenetetrahydrofolic acid 3trebananib 2tivozanib 2pembrolizumab 2Taxes 2Remote Patient Monitoring 2Pemetrexed 2Panitumumab 2Ocoxin 2N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gastrointestinal Neoplasms × camrelizumab × Clear all
NCT02742935 2023-02-27

A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
99 enrolled
BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡